Outcome of the first 3-years of a DNA-based neonatal screening program for glutaric acidemia type 1 in Manitoba and northwestern Ontario, Canada
- PMID: 11825066
- DOI: 10.1006/mgme.2001.3270
Outcome of the first 3-years of a DNA-based neonatal screening program for glutaric acidemia type 1 in Manitoba and northwestern Ontario, Canada
Abstract
Glutaric acidemia type 1 (GA1) is overrepresented in the aboriginal population of Island Lake, Manitoba, and northwestern Ontario who speak the Ojibway-Cree (Oji-Cree) dialect. The carrier frequency in these communities has been predicted to be as high as 1 in 10 individuals. Prior to beginning newborn screening for GA1 in May 1998, 18 of 20 affected patients diagnosed at this center have been from these high-risk communities. Most have followed an acute encephalopathic course with permanent neurologic sequelae and high mortality. They excrete small amounts of glutaric acid and 3-hydroxyglutaric acid and have significant residual enzyme activity. A single homozygous mutation in glutaryl-CoA-dehydrogenase (GCDH IVS-1 + 5g right arrow t) has been identified in this population. DNA-based newborn screening targeted to our high-risk communities was begun in order to provide presymptomatic detection and treatment of affected patients. Of the first 1176 newborns screened, 4 affected infants were identified and treated with a low-protein diet, carnitine, and riboflavin. All 4 infants have required numerous hospitalizations for treatment of intercurrent illnesses. Eventually, 3 infants presented with acute dystonic encephalopathy and seizures along with permanent neurological sequelae. One of these infants died unexpectedly at home at 18 months of age. The fourth, now 9 months old, has had a gastrostomy tube placed to facilitate fluid replacement in addition to a standard treatment protocol and is doing well. The reasons for our initial disappointing outcomes in the first 3 of 4 affected babies are likely multiple. Based on our early experience and that of other centers screening newborns for GA1, current therapeutic strategies may be insufficient in preventing the occurrence of neurologic sequelae in some children. An incomplete understanding of the neurotoxic mechanisms underlying this devastating disorder hampers effective management.
(C)2002 Elsevier Science (USA).
Similar articles
-
Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency.Neuropediatrics. 1996 Jun;27(3):115-23. doi: 10.1055/s-2007-973761. Neuropediatrics. 1996. PMID: 8837070
-
Recurrent and novel mutations of GCDH gene in Chinese glutaric acidemia type I families.Hum Mutat. 2000 Nov;16(5):446. doi: 10.1002/1098-1004(200011)16:5<446::AID-HUMU14>3.0.CO;2-Y. Hum Mutat. 2000. PMID: 11058907
-
Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations.Hum Mutat. 1998;12(3):141-4. doi: 10.1002/(SICI)1098-1004(1998)12:3<141::AID-HUMU1>3.0.CO;2-K. Hum Mutat. 1998. PMID: 9711871 Review.
-
Glutaryl-CoA dehydrogenase deficiency presenting as 3-hydroxyglutaric aciduria.Mol Genet Metab. 1999 Mar;66(3):199-204. doi: 10.1006/mgme.1998.2794. Mol Genet Metab. 1999. PMID: 10066389
-
Acute profound dystonia in infants with glutaric acidemia.Pediatrics. 1989 Feb;83(2):228-34. Pediatrics. 1989. PMID: 2643800 Review.
Cited by
-
Severe neurological manifestations in an Egyptian patient with a novel frameshift mutation in the Glutaryl-CoA dehydrogenase gene.Metab Brain Dis. 2017 Feb;32(1):35-40. doi: 10.1007/s11011-016-9879-x. Epub 2016 Aug 1. Metab Brain Dis. 2017. PMID: 27476540
-
Neonatal screening for glutaric aciduria type I: strategies to proceed.J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):378-82. doi: 10.1007/s10545-006-0284-1. J Inherit Metab Dis. 2006. PMID: 16763905 Review.
-
Clinical, biochemical, neuroradiological and molecular characterization of Egyptian patients with glutaric acidemia type 1.Metab Brain Dis. 2019 Aug;34(4):1231-1241. doi: 10.1007/s11011-019-00422-3. Epub 2019 May 6. Metab Brain Dis. 2019. PMID: 31062211 Free PMC article.
-
Impairment of astrocytic glutaminolysis in glutaric aciduria type I.J Inherit Metab Dis. 2018 Jan;41(1):91-99. doi: 10.1007/s10545-017-0096-5. Epub 2017 Nov 2. J Inherit Metab Dis. 2018. PMID: 29098534
-
Biochemistry and bioenergetics of glutaryl-CoA dehydrogenase deficiency.J Inherit Metab Dis. 2007 Oct;30(5):673-80. doi: 10.1007/s10545-007-0678-8. Epub 2007 Sep 21. J Inherit Metab Dis. 2007. PMID: 17879145
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical